Natera, Inc. (NASDAQ:NTRA) Director Sells $1,548,926.36 in Stock

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 9,682 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $159.98, for a total transaction of $1,548,926.36. Following the completion of the transaction, the director now directly owns 9,704 shares in the company, valued at approximately $1,552,445.92. This represents a 49.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Gail Boxer Marcus also recently made the following trade(s):

• On Thursday, November 14th, Gail Boxer Marcus sold 2,212 shares of Natera stock. The stock was sold at an average price of $158.53, for a total transaction of $350,668.36.

Natera Stock Performance

Shares of NTRA stock traded down $5.60 during mid-day trading on Friday, hitting $163.76. The stock had a trading volume of 354,674 shares, compared to its average volume of 1,342,488. Natera, Inc. has a fifty-two week low of $53.62 and a fifty-two week high of $171.95. The company’s 50-day simple moving average is $129.84 and its 200-day simple moving average is $117.00. The firm has a market cap of $21.62 billion, a PE ratio of -96.14 and a beta of 1.53. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company’s revenue for the quarter was up 63.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.95) earnings per share. Sell-side analysts anticipate that Natera, Inc. will post -1.66 earnings per share for the current year.

Hedge Funds Weigh In On Natera

A number of large investors have recently made changes to their positions in NTRA. Covestor Ltd grew its stake in Natera by 34.3% in the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 95 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares during the last quarter. CIBC Asset Management Inc boosted its holdings in Natera by 3.3% in the third quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock valued at $441,000 after acquiring an additional 111 shares during the last quarter. RiverPark Advisors LLC grew its holdings in shares of Natera by 3.5% during the 3rd quarter. RiverPark Advisors LLC now owns 3,347 shares of the medical research company’s stock worth $425,000 after purchasing an additional 112 shares during the period. Finally, Moss Adams Wealth Advisors LLC lifted its position in Natera by 5.4% during the third quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock valued at $336,000 after buying an additional 135 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on NTRA shares. Canaccord Genuity Group raised their price objective on Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. UBS Group reduced their price objective on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, August 9th. JPMorgan Chase & Co. raised their target price on Natera from $135.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 13th. The Goldman Sachs Group lifted their price objective on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Finally, TD Cowen boosted their target price on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $140.59.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.